ClinicalTrials.gg
Active, not recruitingNCT04214288SERENA-2Updated Aug 26, 2026Results posted

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

A Phase 2 interventional study of AZD9833 and Fulvestrant in Advanced ER-Positive HER2-Negative Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 85 sites in 16 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Neoplasm Metastasis by AstraZeneca — 6 open to participants now, 23 under way, 14 of them phase 3. Neoplasm Metastasis · AstraZeneca.

Enrollment
19th of 55
240 · median 102
Started
2020
with 2 others
Phase 2
13 of 60
none open now
Primary completion
2022-08
later than 3 of 22 live
Registered
42nd of 60
by date

Among the 60 studies in Neoplasm Metastasis by AstraZeneca, this one is the 19th largest by enrollment of the 55 interventional ones that give a count, is one of 3 that started in 2020, is one of 13 in phase 2, reaches primary completion later than 3 of the 22 other live ones, and was the 42nd registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

6 of the 60 studies in Neoplasm Metastasis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Neoplasm Metastasis by AstraZeneca, or all of them as a file.
02

Study summary

This study is randomized, open-label, parallel-group, multicentre Phase 2 study aimed to compare the efficacy and safety of oral AZD9833 versus intramuscular (IM) fulvestrant in women with advanced breast cancer.

Read the detailed description

Post-menopausal women with histologically or cytologically confirmed metastatic or loco-regionally recurrent ER-positive HER2-negative breast cancer before randomization and fulfilling all of the inclusion criteria and none of the exclusion criteria will be included.

After the screening visit and confirmation of eligibility, patients will be randomly assigned in a 1:1:1:1 ratio to receive 1 of the following 4 treatments, consisting of 4-week treatment cycles until disease progression (assessed by the Investigator as defined by Response Evaluation Criteria in Solid Tumours [RECIST] version 1.1):

  • AZD9833 (Dose A)
  • AZD9833 (Dose B)
  • AZD9833 (Dose C)
  • Fulvestrant (500 mg) During the treatment period, patients will have scheduled visits until treatment discontinuation. After the end of treatment, patients will attend 2 safety follow-up visits (at the time of treatment discontinuation and 28 days later) and will continue to be followed for survival.

As of December 2020, the Sponsor stopped enrolment to Dose C.

03

Conditions studied

  • Advanced ER-Positive HER2-Negative Breast Cancer

Browse trials for

Keywords

  • Open-Label
  • Parallel-Group
  • Fulvestrant
  • ER-Positive HER2-Negative Breast Cancer
  • Metastatic
  • AZD9833
  • Oral SERD
  • Camizestrant
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female patients aged at least 18 years.
  • or loco-regionally recurrent ER-positive -negative adenocarcinoma of the breast.
  • Radiological or other objective evidence of progression on or after the last systemic therapy prior to starting study treatment.
  • Patients must have at least 1 lesion, not previously irradiated, that can be measured accurately at baseline as ≥10 mm in the longest diameter or in absence of as defined above, at least 1 lytic or mixed (lytic+sclerotic) bone lesion.
  • (ECOG)/World Health Organisation (WHO) performance status 0 to 1.
  • Prior endocrine therapy as follows:

    1. Recurrence or progression on at least one line of endocrine therapy
    2. No more than 1 line of endocrine therapy for advanced disease
    3. No more than 1 for advanced disease
    4. Prior treatment with CDK4/6 inhibitors is permitted
    5. No prior treatment with fulvestrant, oral selective oestrogen receptor degrader (SERD), or related therapies
  • Inclusion criterion for the paired tumour research subgroup:

Washout from prior tamoxifen: 4 months to elapse from last tamoxifen dose to pre-dose on-study biopsy.

Exclusion criteria

Exclusion Criteria:

Intervention with any of the following:

  • Any cytotoxic chemotherapy, agents or other anti-cancer drugs for the treatment of breast cancer from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.
  • Use of systemic oestrogen-containing hormone replacement therapy within 6 months prior to the first dose of study treatment.
  • Medications or herbal supplements known to be strong inhibitors/inducers of cytochrome P450 3A4/5 and sensitive CYP2B6 substrates, and drugs which are substrates of CYP2C9 and/or CYP2C19 which have a narrow therapeutic index or inability to stop use within the prior to receiving the first dose of study treatment.
  • Drugs that are known to prolong and have a known risk of torsades de pointes.
  • The following cardiovascular criteria: QTcF >470 ms, resting heart rate \<45 bpm, abnormalities of resting , uncontrolled hypertension, symptomatic hypotension, factors that increase the risk for QTc prolongation, \<50%.
  • Radiotherapy with a limited field of radiation for palliation within 1 week of dosing, or to > 30% of bone marrow or a wide field within 4 weeks of dosing.
  • Major surgical procedure or significant traumatic injury.
  • Presence of life-threatening visceral disease or uncontrolled central nervous system metastatic disease.
  • Inadequate bone marrow reserve or organ function.
  • nausea and vomiting, uncontrolled chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of AZD9833.
  • History of to active or inactive of AZD9833 or fulvestrant.
  • Previous randomisation in the present study.
  • Women of .
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    AZD9833 Dose A

    The patients will receive AZD9833 (Dose A).

    Drug: AZD9833

  • Experimental
    AZD9833 Dose B

    The patients will receive AZD9833 (Dose B).

    Drug: AZD9833

  • Experimental
    AZD9833 Dose C

    The patients will receive AZD9833 (Dose C).

    Drug: AZD9833

  • Active comparator
    Fulvestrant 500 mg

    The patients will receive Fulvestrant (500 mg).

    Drug: Fulvestrant

Interventions

  • Dosage formulation: AZD9833 tablets will be administered orally.

  • Dosage formulation: Fulvestrant will be administered via intramuscular (IM) injection.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS was assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1. PFS was defined as the time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or received another anti-cancer therapy prior to progression. Disease progression was defined as ≥20% increase in the sum of diameters of target lesions, unequivocal progression in non-target lesions, and/or appearance of new lesions. Data from the 300mg arm should be interpreted with caution as recruitment to the 300mg arm was stopped early at 20 patients randomised and therefore the 300mg data is highly variable.

    Time frame: From date of randomisation to date of objective disease progression (or last evaluable assessment in the absence of progression) or death (up to data cut-off of 29 months)

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR was assessed by the Investigator as defined by RECIST version 1.1. The ORR was defined as investigator assessed Complete Response or Partial Response prior to progression in patients with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Adjusted response rate was presented in this analysis. Data from the 300mg arm should be interpreted with caution as recruitment to the 300mg arm was stopped early at 20 patients randomised and therefore the 300mg data is highly variable.

    Time frame: From screening until disease progression (up to data cut-off of 29 months)

  2. Duration of Response (DoR)

    DoR was assessed by the Investigator as defined by RECIST version 1.1. The DoR was defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression.

    Time frame: From screening until disease progression or last evaluable assessment in the absence of progression (up to data cut-off of 29 months)

  3. Percentage Change in Tumour Size at 16 Weeks

    The percentage change in tumour size at 16 weeks was obtained for each patient, based on RECIST measurements taken at baseline and at 16 weeks. Tumour size is the sum of the longest diameters of the target lesions (TLs). Percentage change in the sum of longest TLs diameters at 16 weeks was measured.

    Time frame: At Week 16

  4. Overall Survival (OS)

    The OS was defined as the time from randomisation to death due to any cause.

    Time frame: From the date of randomisation until death (up to data cut-off of 29 months)

  5. Clinical Benefit Rate at 24 Weeks (CBR24)

    Clinical benefit rate was defined as patients with best objective response of complete response or partial response in the first 25 weeks or who have stable disease for at least 23 weeks after randomization. Adjusted response rate was presented in this analysis. Data from the 300mg arm should be interpreted with caution as recruitment to the 300mg arm was stopped early at 20 patients randomised and therefore the 300mg data is highly variable.

    Time frame: At Week 24

  6. Plasma Concentrations of AZD9833

    The plasma concentrations of AZD9833 at steady state were evaluated.

    Time frame: Cycle 1 Day 15 (pre-dose), Cycle 1 Day 15 (2h), Cycle 1 Day 15 (4h) and Cycle 2 Day 1 (pre-dose), (each cycle is 28 days in length)

  7. Percent Change From Baseline in ER and PgR Expression and Ki67 Labelling Index

    The pharmacodynamics of AZD9833 and fulvestrant in a subgroup of patients.

    Time frame: From baseline to Cycle 2 Day 1 (each cycle is 28 days in length)

  8. Changes From Baseline in Health Related Quality of Life (HRQoL)

    To evaluate the effect of AZD9833 and fulvestrant on the patients' health-related quality of life, as assessed by patient completed HRQoL questionnaires.

    Time frame: From Day 1 until end of treatment and safety follow up (up to data cut-off of 29 months)

Other outcomes

  1. Number of Patients With Adverse Events

    The safety and tolerability of AZD9833 when compared to fulvestrant in women with advanced ER-positive HER2-negative breast cancer was evaluated.

    Time frame: From the date of first dose up to the safety follow-up period (28 days after last dose of AZD9833 and 56 days after last dose of fulvestrant) (up to data cut-off of 29 months)

07

Results

Posted Dec 12, 2023
Limitations and caveats
At the time of CSR finalization, CSP version 5.0 was available, therefore, CSP version 5.0 was redacted and submitted along with the Results Registration Form. Data from the 300mg arm should be interpreted with caution as recruitment to the 300mg arm was stopped early at 20 patients randomised and therefore the 300mg data is highly variable.

Participant flow

The patients were enrolled at 82 sites in 16 countries from 22 April 2020 to 30 August 2022. The study is ongoing.

Participant flow — Overall Study
MilestoneAZD9833 75mgAZD9833 150mgAZD9833 300mgFulvestrant 500 mg
Started74732073
Completed0000
Not completed74732073
Withdrew: Ongoing in the study41511239
Withdrew: Adverse event1000
Withdrew: Death2213719
Withdrew: Lost to follow-up1210
Withdrew: Other1206
Withdrew: Protocol violation0100
Withdrew: Withdrawal by subject8409

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS was assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1. PFS was defined as the time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or received another anti-cancer therapy prior to progression. Disease progression was defined as ≥20% increase in the sum of diameters of target lesions, unequivocal progression in non-target lesions, and/or appearance of new lesions. Data from the 300mg arm should be interpreted with caution as recruitment to the 300mg arm was stopped early at 20 patients randomised and therefore the 300mg data is highly variable.

Time frame:
From date of randomisation to date of objective disease progression (or last evaluable assessment in the absence of progression) or death (up to data cut-off of 29 months)
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsAZD9833 75mgAZD9833 150mgAZD9833 300mgFulvestrant 500 mg
Progression-free Survival (PFS)7.2 (3.7 to 10.9)7.7 (5.5 to 12.9)6.3 (1.9 to NA)3.7 (2.0 to 6.0)
Statistical analysis
  • AZD9833 75mg vs Fulvestrant 500 mg · Log Rank · p = 0.0167 · Hazard ratio (hr): 0.59 · 90% CI 0.42 to 0.82A hazard ratio \< 1 favours AZD9833 to be associated with a longer progression-free survival than fulvestrant.
  • AZD9833 150mg vs Fulvestrant 500 mg · Log Rank · p = 0.0090 · Hazard ratio (hr): 0.64 · 90% CI 0.46 to 0.89A hazard ratio \< 1 favours AZD9833 to be associated with a longer progression-free survival than fulvestrant.
SecondaryObjective Response Rate (ORR)

ORR was assessed by the Investigator as defined by RECIST version 1.1. The ORR was defined as investigator assessed Complete Response or Partial Response prior to progression in patients with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Adjusted response rate was presented in this analysis. Data from the 300mg arm should be interpreted with caution as recruitment to the 300mg arm was stopped early at 20 patients randomised and therefore the 300mg data is highly variable.

Time frame:
From screening until disease progression (up to data cut-off of 29 months)
Reported as:
Number · Percentage (%)
Objective Response Rate (ORR)
Percentage (%)AZD9833 75mgAZD9833 150mgAZD9833 300mgFulvestrant 500 mg
Objective Response Rate (ORR)15.717.125.211.6
Statistical analysis
  • AZD9833 75mg vs Fulvestrant 500 mg · Regression, Logistic · p = 0.4828 · Odds ratio (or): 1.42 · 90% CI 0.63 to 3.31An odds ratio \> 1 favours AZD9833.
  • AZD9833 150mg vs Fulvestrant 500 mg · Regression, Logistic · p = 0.3691 · Odds ratio (or): 1.57 · 90% CI 0.69 to 3.67An odds ratio \> 1 favours AZD9833.
SecondaryDuration of Response (DoR)

DoR was assessed by the Investigator as defined by RECIST version 1.1. The DoR was defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression.

Time frame:
From screening until disease progression or last evaluable assessment in the absence of progression (up to data cut-off of 29 months)

Results for this outcome have not been posted.

SecondaryPercentage Change in Tumour Size at 16 Weeks

The percentage change in tumour size at 16 weeks was obtained for each patient, based on RECIST measurements taken at baseline and at 16 weeks. Tumour size is the sum of the longest diameters of the target lesions (TLs). Percentage change in the sum of longest TLs diameters at 16 weeks was measured.

Time frame:
At Week 16

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

The OS was defined as the time from randomisation to death due to any cause.

Time frame:
From the date of randomisation until death (up to data cut-off of 29 months)

Results for this outcome have not been posted.

SecondaryClinical Benefit Rate at 24 Weeks (CBR24)

Clinical benefit rate was defined as patients with best objective response of complete response or partial response in the first 25 weeks or who have stable disease for at least 23 weeks after randomization. Adjusted response rate was presented in this analysis. Data from the 300mg arm should be interpreted with caution as recruitment to the 300mg arm was stopped early at 20 patients randomised and therefore the 300mg data is highly variable.

Time frame:
At Week 24
Reported as:
Number · Percentage (%)
Clinical Benefit Rate at 24 Weeks (CBR24)
Percentage (%)AZD9833 75mgAZD9833 150mgAZD9833 300mgFulvestrant 500 mg
Clinical Benefit Rate at 24 Weeks (CBR24)48.851.042.439.1
Statistical analysis
  • AZD9833 75mg vs Fulvestrant 500 mg · Regression, Logistic · p = 0.2554 · Odds ratio (or): 1.48 · 90% CI 0.84 to 2.64An odds ratio \> 1 favours AZD9833.
  • AZD9833 150mg vs Fulvestrant 500 mg · Regression, Logistic · p = 0.1658 · Odds ratio (or): 1.62 · 90% CI 0.91 to 2.89An odds ratio \> 1 favours AZD9833.
SecondaryPlasma Concentrations of AZD9833

The plasma concentrations of AZD9833 at steady state were evaluated.

Time frame:
Cycle 1 Day 15 (pre-dose), Cycle 1 Day 15 (2h), Cycle 1 Day 15 (4h) and Cycle 2 Day 1 (pre-dose), (each cycle is 28 days in length)
Reported as:
Geometric mean · ng/ml
Plasma Concentrations of AZD9833
ng/mlAZD9833 75mgAZD9833 150mgAZD9833 300mg
Cycle 1 Day 15 (pre-dose)22.8387 ± 84.320741.0856 ± 148.5806108.1351 ± 157.3080
Cycle 1 Day 15 (2h)51.9098 ± 94.463296.2038 ± 164.5328302.1254 ± 66.9155
Cycle 1 Day 15 (4h)54.5098 ± 87.215295.5360 ± 160.0032289.1464 ± 68.1607
Cycle 2 Day 1 (pre-dose)24.2895 ± 88.414034.2592 ± 245.9897115.8558 ± 156.4858
SecondaryPercent Change From Baseline in ER and PgR Expression and Ki67 Labelling Index

The pharmacodynamics of AZD9833 and fulvestrant in a subgroup of patients.

Time frame:
From baseline to Cycle 2 Day 1 (each cycle is 28 days in length)

Results for this outcome have not been posted.

SecondaryChanges From Baseline in Health Related Quality of Life (HRQoL)

To evaluate the effect of AZD9833 and fulvestrant on the patients' health-related quality of life, as assessed by patient completed HRQoL questionnaires.

Time frame:
From Day 1 until end of treatment and safety follow up (up to data cut-off of 29 months)

Results for this outcome have not been posted.

Other pre-specifiedNumber of Patients With Adverse Events

The safety and tolerability of AZD9833 when compared to fulvestrant in women with advanced ER-positive HER2-negative breast cancer was evaluated.

Time frame:
From the date of first dose up to the safety follow-up period (28 days after last dose of AZD9833 and 56 days after last dose of fulvestrant) (up to data cut-off of 29 months)
Reported as:
Count of participants · Participants
Number of Patients With Adverse Events
ParticipantsAZD9833 75mgAZD9833 150mgAZD9833 300mgFulvestrant 500 mg
Any Adverse Event (AE)57661950
Any AE causally related to treatment39491413
Any AE of CTCAE grade 3 or higher917311
Any AE of CTCAE grade 3 or higher, causally related to treatment1210
Any AE with outcome = death0100
Any AE with outcome = death, causally related to treatment0000
Any Serious Adverse Event (SAE)6724
Any SAE, causally related to treatment3210
Any SAE causing discontinuation of treatment1000
Any SAE causing discontinuation of treatment, causally related to treatment1000
Any AE leading to discontinuation of treatment2020
Any AE leading to discontinuation of treatment, causally related to treatment2000
Any AE leading to dose reduction1940
Any AE leading to dose interruption111643

Adverse events

Collected over From the date of first dose up to the safety follow-up period (28 days after last dose of AZD9833 and 56 days after last dose of fulvestrant) (up to data cut-off of 29 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AZD9833 75mg23/74 (31.1%)6/74 (8.1%)44/74 (59.5%)
AZD9833 150mg14/73 (19.2%)7/73 (9.6%)61/73 (83.6%)
AZD9833 300mg7/20 (35%)2/20 (10%)17/20 (85%)
Fulvestrant 500 mg21/73 (28.8%)4/73 (5.5%)31/73 (42.5%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventAZD9833 75mgAZD9833 150mgAZD9833 300mgFulvestrant 500 mg
Breast cellulitisInfections and infestations0/741/70/200/73
COVID-19 pneumoniaInfections and infestations0/741/70/200/73
COVID-19Infections and infestations0/740/71/200/73
International normalised ratio increasedInvestigations0/740/731/200/73
HyponatraemiaMetabolism and nutrition disorders0/741/730/200/73
Cerebrovascular accidentNervous system disorders0/741/730/200/73
Atrial fibrillationCardiac disorders0/741/730/201/73
Atrial tachycardiaCardiac disorders0/741/730/200/73
Supraventricular tachycardiaCardiac disorders0/740/730/201/73
Pleural effusionRespiratory, thoracic and mediastinal disorders0/741/730/201/73
Most frequent other events
Showing 10 of 34
Most frequent other events
EventAZD9833 75mgAZD9833 150mgAZD9833 300mgFulvestrant 500 mg
PhotopsiaEye disorders9/7418/737/200/73
BradycardiaCardiac disorders0/7412/736/200/73
FatigueGeneral disorders4/7414/734/203/73
AnaemiaBlood and lymphatic system disorders7/7411/731/205/73
AstheniaGeneral disorders6/7411/732/205/73
DiarrhoeaGastrointestinal disorders4/744/733/202/73
Alanine aminotransferase increasedInvestigations1/746/733/204/73
ArthralgiaMusculoskeletal and connective tissue disorders3/749/732/203/73
COVID-19Infections and infestations4/744/732/203/73
HyponatraemiaMetabolism and nutrition disorders0/742/732/201/73

Baseline characteristics

Full Analysis Set (FAS) consisted of all randomised patients, with treatment groups assigned in accordance with the randomisation, regardless of the actual treatment received.

Age, Continuous
Age, Continuous(Years)AZD9833 75mgAZD9833 150mgAZD9833 300mgFulvestrant 500 mgTotal
Mean61.2 ± 9.5661.7 ± 9.6859.9 ± 10.7259.3 ± 11.0860.7 ± 10.16
Sex: Female, Male
Sex: Female, Male(Participants)AZD9833 75mgAZD9833 150mgAZD9833 300mgFulvestrant 500 mgTotal
Female74732073240
Male00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AZD9833 75mgAZD9833 150mgAZD9833 300mgFulvestrant 500 mgTotal
Black or African American00022
White71702065226
Other330612
08

Study locations

85 sites
  • Research Site
    Birmingham, Alabama 35205, United States
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    Fort Myers, Florida 33901, United States
  • Research Site
    St. Petersburg, Florida 33705, United States
  • Research Site
    Lincoln, Nebraska 68506, United States
  • Research Site
    Canton, Ohio 44710, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Eagle River, Wisconsin 54521, United States
  • Research Site
    Brasschaat, 2930, Belgium
  • Research Site
    Charleroi, 6000, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Haine-Saint-Paul, 7100, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Libramont-Chevigny, 6800, Belgium
  • Research Site
    Namur, 5000, Belgium
  • Research Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • Research Site
    Montreal, Quebec H1T 2M4, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Paris, 75005, France
  • Research Site
    Vandœuvre-lès-Nancy, 54519, France
  • Research Site
    Batumi, 6000, Georgia
  • Research Site
    Tbilisi, '0112, Georgia
  • Research Site
    Tbilisi, '0159, Georgia
  • Research Site
    Tbilisi, '0186, Georgia
  • Research Site
    Tbilisi, 0159, Georgia
  • Research Site
    Tbilisi, 0186, Georgia
  • Research Site
    Berlin, 10707, Germany
  • Research Site
    Düsseldorf, 40225, Germany
  • Research Site
    Essen, 45136, Germany
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Kaposvár, 7400, Hungary
  • Research Site
    Kecskemét, 6000, Hungary
  • Research Site
    Nyíregyháza, 4400, Hungary
  • Research Site
    Pécs, 7624, Hungary
  • Research Site
    Szeged, 6725, Hungary
  • Research Site
    Jerusalem, 91031, Israel
  • Research Site
    Jerusalem, 9112001, Israel
  • Research Site
    Nahariya, 22100, Israel
  • Research Site
    Petah Tikva, 4941492, Israel
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Catanzaro, 88100, Italy
  • Research Site
    Meldola, 47014, Italy
  • Research Site
    Messina, 98158, Italy
  • Research Site
    Milan, 20141, Italy
  • Research Site
    Milan, 20121, Italy
  • Research Site
    Monza, 20900, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Roma, 00128, Italy
  • Research Site
    Umbria, 5100, Italy
  • Research Site
    Bydgoszcz, 85-796, Poland
  • Research Site
    Lodz, 93-513, Poland
  • Research Site
    Piła, 64-920, Poland
  • Research Site
    Rzeszów, 35-021, Poland
  • Research Site
    Skorzewo, 60-185, Poland
  • Research Site
    Warsaw, 02-781, Poland
  • Research Site
    Almada, 2805-267, Portugal
  • Research Site
    Lisbon, 1400-038, Portugal
  • Research Site
    Lisbon, 1449-005, Portugal
  • Research Site
    Lisbon, 1998-018, Portugal
  • Research Site
    Kazan', 420029, Russia
  • Research Site
    Krasnodar, 350040, Russia
  • Research Site
    Kursk, 305035, Russia
  • Research Site
    Moscow, 115478, Russia
  • Research Site
    Moscow, 123056, Russia
  • Research Site
    Pyatigorsk, 357502, Russia
  • Research Site
    Ryazan, 390011, Russia
  • Research Site
    Saint Petersburg, 197082, Russia
  • Research Site
    Saint Petersburg, 197758, Russia
  • Research Site
    Volgograd, 400138, Russia
  • Research Site
    Goyang-si, 10408, South Korea
  • Research Site
    Incheon, 405-760, South Korea
  • Research Site
    Barcelona, 08190, Spain
  • Research Site
    Madrid, 28050, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Zaragoza, 50009, Spain
  • Research Site
    Cherkasy, 18009, Ukraine
  • Research Site
    Chernivtsі, 58013, Ukraine
  • Research Site
    Kyiv, 03039, Ukraine
  • Research Site
    M. Kyiv, 02094, Ukraine
  • Research Site
    S. Khodosivka, 08173, Ukraine
  • Research Site
    Uzhhorod, 88000, Ukraine
  • Research Site
    Derby, DE22 3NE, United Kingdom
  • Research Site
    Leicester, LE1 5WW, United Kingdom
09

References and documents

Publications

  • Oliveira M, Pominchuk D, Nowecki Z, Hamilton E, Kulyaba Y, Andabekov T, Hotko Y, Melkadze T, Nemsadze G, Neven P, Vladimirov V, Zamagni C, Denys H, Forget F, Horvath Z, Nesterova A, Ajimi M, Kirova B, Klinowska T, Lindemann JPO, Lissa D, Mathewson A, Morrow CJ, Traugottova Z, van Zyl R, Arkania E. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol. 2024 Nov;25(11):1424-1439. doi: 10.1016/S1470-2045(24)00387-5. PubMed 39481395 ↗
  • Hamilton E, Oliveira M, Turner N, Garcia-Corbacho J, Hernando C, Ciruelos EM, Kabos P, Ruiz-Borrego M, Armstrong A, Patel MR, Vaklavas C, Twelves C, Boni V, Incorvati J, Brier T, Gibbons L, Klinowska T, Lindemann JPO, Morrow CJ, Sykes A, Baird RD. A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results. Ann Oncol. 2024 Aug;35(8):707-717. doi: 10.1016/j.annonc.2024.04.012. Epub 2024 May 8. PubMed 38729567 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Aug 2022, 28 months.

Results were first posted in Dec 2023, 1 year 3 months after primary completion.

Of 88 industry-sponsored phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's 28 months is below that.

Counting every sponsor, half of 443 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2019
First posted
Jan 2, 2020
StartActual
Apr 22, 2020
Primary completionActual
Aug 30, 2022
CompletionEst.
Jun 16, 2027
Results first posted
Dec 12, 2023
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04214288
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 2, 2020
Start date
Apr 22, 2020
Primary completion
Aug 30, 2022
Completion
Jun 16, 2027 (estimated)
Results posted
Dec 12, 2023
Last update
Aug 26, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD9833

Start the discussion